Second, the outcomes mentioned in this study did help us to evaluate the effects of dabrafenib combined with trametinib in BRAF V600 mutation-positive glioma to a great extent, but if there are more high-quality studies in the future, we may make a more comprehensive evaluation together with other more evaluation items, such as neurocognitive and psychological evaluation, which depended on a fact that BRAF V600 mutation-positive glioma survivors face long-term psychological and neurocognitive morbidities [39].Thirdly, the studies included in this study was limited. This evidence concerns the gene BRAF and central nervous system cancer.